RBC Capital Upgrades KP Tissue to Outperform, Raises Price Target to C$12
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Paul Quinn has upgraded KP Tissue from Sector Perform to Outperform and raised the price target from C$10 to C$12.
July 19, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KP Tissue's rating has been upgraded to Outperform by RBC Capital, with a raised price target of C$12.
The upgrade from RBC Capital is a positive signal for KP Tissue. The raised price target indicates that the analyst sees potential for the stock's price to increase, which could attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100